Boehringer licenses NSCLC therapy from Hanmi

Boehringer Ingelheim GmbH (Ingelheim, Germany) obtained exclusive, worldwide rights, excluding certain Asian territories, to lung cancer treatment HM61713 from Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940).

Boehringer will receive rights to the EGFR mutant selective inhibitor outside South Korea, China and Hong Kong. HM61713 is in a Phase II trial to treat non-small cell lung cancer in patients with T790M mutations who are resistant to other therapies targeting EGFR. The partners, which did not respond to inquiries, expect a Phase III trial to begin next year. ...